Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.52 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21690039 | 1.00 | KMT2A (0.57) | KMT2ASMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL21689926 | 0.87 | ITGB1 (0.66) | ITGB1ITGA4ITGB7 | |
| SCHEMBL13383323 | 0.86 | KMT2A (0.55) | KMT2ASMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL21690040 | 0.84 | FKBP1A (0.65) | KMT2ASMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL21690440 | 0.81 | KMT2A (0.58) | KMT2ASMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL21689918 | 0.81 | KMT2A (0.58) | KMT2ASMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL21689981 | 0.81 | ACACB (0.56) | KMT2ASMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL8299831 | 0.81 | ITGA4 (0.57) | KMT2ASMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL23194179 | 0.80 | CACNA1B (0.45) | KMT2ASMN1; SMN2MEN1ITGB1ITGA4 | |
| SCHEMBL8278642 | 0.79 | ITGA4 (0.79) | KMT2ASMN1; SMN2RAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | KMT2A 4739/4885SMN1; SMN2 4722/4885RAB9A 2135/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KMT2A 4739/4885SMN1; SMN2 4722/4885RAB9A 2135/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KMT2A 4739/4885SMN1; SMN2 4722/4885RAB9A 2135/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KMT2A 4739/4885SMN1; SMN2 4722/4885RAB9A 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.